Background: Macaques are outstanding animal models for the development of new contraceptives. In women, progestin-only contraceptives often fail to block ovulation and are believed to act by altering cervix physiology. Herein, we assessed oviductal glycoprotein 1 (OVGP1) in the macaque cervix as a marker for progestogen action.
| INTRODUC TI ON
Estrogen-free contraceptives benefit women with contraindications for estrogen therapy. 1 The most common estrogen-free hormonal methods are the progestin-only contraceptives that act by either suppressing ovulation 2 or by altering cervical mucus secretion. 3 Unfortunately, some women also display unwanted side effects of progestin therapy, such as breakthrough bleeding 4 and weight gain. 5 Identifying novel completely hormone-free methods that specifically target cervical mucus secretion would benefit women who cannot use hormonal methods.
Non-human primates, especially macaques, are excellent animal models for the studies of reproductive tract physiology and for the development of new contraceptives in advance of clinical trials in women. 6, 7 In women, the effect of hormones on the cervix has been traditionally evaluated by Insler score of cervical mucus. 8, 9 Insler scoring examines such aspects as ferning, spinnbarkeit (stretchability), the volume of an aspirate, cellularity, and perceived viscosity.
The Insler scoring system combines quantitative values with subjective values to produce a total, semiquantitative score. 10 Insler score was initially developed for identifying the fertile period of the human menstrual cycle; in practice, the effect of contraceptives on cervical mucus is difficult to assess accurately. 10 Although it is possible to replicate cervical mucus scoring in the macaque, 11, 12 the volume of mucus in the presence of progestins is often close to the limit of measurement in the luteal phase of the menstrual cycle. Therefore, there are currently no reliable markers for identifying the action of contraceptive progestins in the macaque.
In a preliminary study, we carried out a GeneChip™ Genome
Array analysis of cervix RNA from cycling rhesus macaques. Oviductal glycoprotein 1 (OVGP1; MUC9) was identified as transcript expressed in the cervix arrays. OVGP1 is a carbohydrate-rich glycoprotein secreted by oviductal epithelial cells that has spermbinding properties. 14, 15 Early studies of the macaque and baboon oviduct report that estrogen stimulates and progestogens suppress OVGP1. 16 OVGP1 is expressed in the cervix of rabbits 17 and primates, 13 but hormonal regulation is undocumented. We hypothesized that OVGP1 could be hormonally regulated in the cervix and provide a marker for progestogen action. To test this hypothesis, we characterized hormonal regulation and localization of OVGP1 in the cervix of hormone-treated macaques. Our goal was to develop a molecular marker of progestogen action in cervix epithelial cells of macaques.
| MATERIAL S AND ME THODS

| Humane care guidelines
The Oregon National Primate Research Center (ONPRC), Division 
| Treatments & Samples
To conserve animal resources, we first analyzed archived samples of rhesus macaque (Macaca mulatta) cervix. The samples were obtained at necropsy from adult oophorectomized animals treated sequentially with subcutaneous silastic capsules 18 that released either estradiol (E 2 ) or progesterone (P) to create controlled artificial menstrual cycles (Figure 1 ). The capsules produced normal proliferative phase levels of E 2 (80-100 pg/mL) and secretory phase levels of P (5-7 ng/mL) as previously reported. 19, 20 Treatments and time points are shown in Table 1 . Similar samples were also obtained from ova- were 97 ± 17 pg/mL) and secretory phase (cycle day 17-23) E 2 and P levels were 85 ± 11 pg E 2 , and 5.6 ± 6.1 ng P/mL, respectively.
Briefly, the animals were sedated with ketamine ( The slides were then either immediately stained with hematoxylin cover slipped with glycerin and photographed or fixed in with 4%
paraformaldehyde for 10 minutes at room temperature and subjected to IHC. Table 2 shows PCR primers and hydrolysis probes. Target genes' expression was referenced to Ribosomal S10 RNA expression 21 and averaged to give a single level of expression.
| RNA analysis
RT-qPCR data were examined for statistical outliers using Grubbs' test 22 and then evaluated Levene's test for equality of variance.
Datasets were transformed (log 10 + 1) to correct for heterogeneity and then analyzed by analysis of variance followed by Fisher's LSD test for comparison of means. 23 Untransformed mean (±standard errors; SE) was plotted using Origin Lab (Version 9; Northhampton, MA, USA) Software.
Conventional RT-PCR was conducted on a subset of samples to validate RT-qPCRs ( Figure 3A ). Total RNA was reverse transcribed into cDNA as described above. 1 μg of cDNA was amplified using a HotStar Taq PCR (Qiagen) kit with 3 step cycling for 30 cycles.
For each cycle, denaturation was 0.75 minute at 94°C; annealing was 0.75 minute at 68°C; extension was 1 minute at 72°C. PCR products were visualized after fractionation on 1% agarose gels in the presence of ethidium bromide.
| Western blot
Anti-OGP1 (Abcam cat #118590, Cambridge, MA, USA) antibody specificity was demonstrated by Western blot ( Figure 3B ). 
| Immunohistochemistry
Immunohistochemistry for OVGP1 was conducted on (6 μm) paraffin sections using a standardized technique 21 at room temperature unless otherwise noted. The sections were mounted on SuperFrost Plus slides and allowed 3 days for full adherence to the slides. The slides were deparaffinized in xylene and rehydrated. Antigen 24 to show specific staining in macaque oviduct and ovarian surface epithelium.
Immunohistochemistry for ESR1 and PGR was conducted on 7 μm cryosections as previously described. 18 Target-specific antibodies were anti-ESR1 (estrogen receptor 1) Neomarkers cat#Ms-354-P), and an antiprogesterone receptor IgG that detects both isoforms of PGR (anti-PGR; Neomarkers, Freemont, CA, USA, cat#Ms-298-P). Antibody concentrations for ESR1 and PGR have been published previously. Digital images were taken using a Zeiss Axiolmager A.I microscope (Carl Zeiss, Inc., Oberkochen, Germany) and a Leica DFC 480 camera (Leica, Wetzler, Germany).
F I G U R E 3 Blots showing OVGP1 analysis by conventional PCR and Western Blot with ab 11850. A, RT-PCR analysis demonstrating probe specificity, and Western blot (B) showing antibody specificity
| RE SULTS
| OVGP1 Transcript expression
Conventional RT-PCR revealed a single-specific band in proliferative phase samples but nearly absent in secretory phase samples ( Figure 3A) . Figure 4 shows levels of OVGP1 transcript detected by RT-qPCR. Based on RT-qPCR OVGP1 was present in all samples analyzed. The cyclic patterns revealed that OVGP1 transcript was minimal in the premenstrual and menstrual phase of the cycle.
Levels increased significantly (P < .05) during the proliferative phase and maximal on day 1 of the secretory phase. After that, levels OVGP1transcript decreased to baseline by day 3 of P treatment and remained low throughout the secretory phase. Figure 4B shows a comparison of treatment with E 2 alone or with E 2 plus LNG for 28 days. Treatment with LNG significantly reduced OVGP1 transcript compared with E 2 alone (P < .05) similar to the late secretory phase. RT-qPCR also revealed OVGP1 transcript in cervix epithelial cells collected by cytobrush ( Figure 4C ). Levels were elevated in the proliferative phase and significantly suppressed in the secretory phase (P < .05). phase of the cycle ( Figure 5C ). No specific staining was detected in the cervix stroma. Minimal staining, approaching background was detected in the cervix during the secretory phase ( Figure 5B ). Only hematoxylin background staining was observed after treatment with LNG ( Figure 5G) . Figure 5E ,F shows staining for ab 74544. Ab 74544 also showed stronger staining in the cervix epithelium from the proliferative phase than secretory phase, but also shows unexpected staining in stromal and endothelial cells. As expected, samples of ampulla ( Figure 5C ) revealed strong staining for OVGP1 with ab 119590, which was decreased in the secretory phase ( Figure 5D ).
| OVGP1 immunostaining
Oviductal ampulla revealed strong epithelial staining as reported by
Wright et al 24 (not shown). 
| Steroid receptor expression and immunostaining
| D ISCUSS I ON
Oviductal glycoprotein 1 is an estrogen-dependent mucin that is secreted by the fallopian tube of women, primates and non-primate species. 14,27,28 OVGP1 protein has also isolated from the mammalian cervix 17 (eg, MUC9). Early studies suggested that OVGP1 expression was restricted to the oviductal epithelium and focused primarily on a potential role for OVGP1 on gamete interactions. 29 More recently, studies report that OVGP1 is also expressed by ovarian epithelium 30 and some reproductive tract carcinomas. [30] [31] [32] We report that OVGP1 is expressed by epithelial cells of the macaque cervix and strongly in the proliferative phase and downregulated in the secretory phase of the artificial menstrual cycle. Overall, OVGP1 levels parallel other estrogen-regulated target including PGR and are increased at points in the cycle when cervical mucus secretion is reported to be high. 11, 12 In this study, we assessed 2 antibodies for OVGP1 (ab1185090 and ab74544), which in theory, detect the multiple moieties with for sperm-mucus interaction, but is highly variable, subjective, difficult to execute and most importantly, unvalidated in nonhuman primates. The strength of our artificial cycle non-human primate model is that the cycles are driven solely by changes in the exposure to E 2 and P. In this model, we can clearly test the effects of controlled levels of E 2 and P and we demonstrate that OVGP1 expression not only increases during estrogen treatment but is suppressed by P in the presence of continued exposure to E 2 . Therefore, downregulation of OVGP1 in the secretory phase is due specifically to the action of progestogen. This is
Immunostaining for ESR1(A,B) and PGR (C,D). RT-qPCR analysis of ESR1 and PGR mRNA expression shows significant upregulation of both ESR1 and PGR in the proliferative phase of the cycle (E) physiologically relevant because the primate corpus luteum produces significant levels of estrogen during the natural menstrual cycle. The significance of this outcome is underscored by the observation that treatment with E 2 plus the contraceptive progestin, LNG, also displayed reduced levels of OVGP1 transcript compared with E 2 treatment alone. Therefore, we propose that OVGP1 should provide a realistic molecular marker of progestin action on cervix mucin production.
Progestin downregulation of OVGP1 is further supported by effect of LNG. LNG appears to result in a greater suppression of OVGP1 than P in the artificial cycle. LNG is primarily a progesterone receptor agonist, with weak androgen action. 33 There is substantial overlap in the transcriptional response to progestogens and androgens in cells that express both receptors. It is also likely that the prolonged 28-day LNG further reduced OVGP1 compared with the 14-day secretory phase.
Unlike other compartments of the female reproductive tract, the cervical epithelium is easily accessible by biopsy or cervical brush. We have demonstrated that RNA can be isolated from these cells and assayed by RT-qPCR for OVGP1 to produce a rapid, sensitive assay for contraceptive progestin action. It is well documented that OVGP1 is secreted into the oviductal fluid, and it is likely that it is also secreted into cervical mucus. OVGP1 is reported to have interactions with sperm as well as zona pellucida, sperm health before fertilization. 14 However, the physiolog- 
| CON CLUS ION
In conclusion, we propose that cervix epithelium collected by cytobrush and assayed for OVGP1 expression by RT-qPCR can provide a rapid and very sensitive method for identifying the effect of progestogen-based contraceptives on the cervix in preclinical experiments in cycling monkeys and clinical trials. 
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